EDAP TMS S.A. American Depositary Shares (FOCL) Company Overview

EDAP TMS S.A., operating as FocalTherics and trading on Nasdaq as FOCL, is a French medical-device company focused on robotic high-intensity focused ultrasound, or HIFU. Its Focal One platform helps urologists image, plan, target, and thermally ablate selected prostate tissue without an incision. The strategic aim is to establish focal therapy between active surveillance and whole-gland treatment.

Why does the company matter in focal therapy?

Focal One combines real-time ultrasound imaging, treatment planning, robotic probe positioning, and focused energy delivery in one workflow. The latest Focal One i configuration received U.S. Food and Drug Administration clearance in November 2025 for transrectal HIFU ablation of prostate tissue. The FDA decision summary classifies the system as a Class II device, while the official Focal One platform site explains the integrated imaging and robotic treatment workflow.

The model combines capital-equipment placements with revenue generated after installation. Hospitals may buy or lease Focal One, while other arrangements pay FocalTherics per procedure. The company also sells consumables, spare parts, and maintenance. Placements create equipment revenue; utilization builds recurring treatment and service revenue.

How much revenue is recurring versus equipment-driven?

FY2025 revenue included $48.9 million of goods, $10.3 million of revenue-per-procedure and leases, and $11.3 million of spare parts and services. Goods were 69.3% of total revenue; recurring and service-oriented categories were 30.7%. Because the figures include legacy products, they are not a pure HIFU mix.

Which business segment now matters most?

HIFU was 53.0% of FY2025 revenue, up from 37.2% in FY2024. HIFU device sales were $18.1 million, treatment-driven revenue was $16.1 million, and maintenance was $3.1 million. The company sold 35 Focal One units in FY2025, including 20 in the United States, versus 22 units, including 12 U.S. units, in FY2024.

Q1 2026 showed the pivot advancing faster in revenue than in profitability. Total revenue rose 24.8% to $17.8 million, while HIFU revenue rose 78.3% to $11.6 million. FocalTherics shipped 11 systems, five in the United States, versus six systems, two in the United States, a year earlier. U.S. procedure volume grew 53%.

What improved in Q1 2026?

Why did the loss still widen?

Q1 2026 operating expenses were about $15.5 million: $7.1 million of selling and marketing, $5.8 million of general and administrative expense, and $2.6 million of R&D. Operating margin was about negative 41.4% and net margin about negative 51.0%. Commercialization and clinical investment still run ahead of gross profit.

The latest Form 10-Q for Q1 2026 provides the detailed statements, while the official quarterly results release highlights placements and procedure growth.

FocalTherics is a strategic migration from diversified urology equipment toward a focused robotic therapy platform. The milestones below changed its regulatory foundation, evidence base, commercial model, or capital needs.

1. 1979
   Founded in France. The company developed decades of therapeutic-ultrasound and urology-device engineering that now underpins Focal One.
2. 1997
   Nasdaq ADS listing. Access to U.S. public capital eventually became essential for a global clinical and commercialization strategy.
3. 2018
   Focal One received U.S. 510(k) clearance. The platform could begin building a U.S. installed base rather than remaining primarily European.
4. 2023
   Ryan Rhodes became chief executive officer. Management accelerated U.S. placements, procedure growth, and the shift toward focal therapy.
5. 2024
   ESWL manufacturing ended. That decision reduced commitment to a declining legacy product line and made the HIFU pivot more explicit.
6. 2025
   HIFU revenue reached $37.4M and the updated Focal One i received FDA clearance. Commercial scale and product modernization advanced together.
7. 2026
   FocalTherics and FOCL became the corporate brand and ticker. Management also announced its intention to present ESWL and Distribution as discontinued operations beginning in Q2 2026.

The legal issuer remains EDAP TMS S.A., while corporate communications use FocalTherics and legacy operations are planned for discontinued presentation. See the official identity announcement.

The potential moat is a system, not one patent. Focal One combines a specialized robot, clinical evidence, physician training, treatment-planning software, service capability, and a growing installed base. Hospitals also build referral, reimbursement, and operating workflows around the platform, creating practical switching costs.

How strong is the evidence and installed-base position?

The HIFI study included 3,328 patients at 46 centers: 1,967 received HIFU and 1,361 radical prostatectomy. Company materials report non-inferiority on salvage-treatment-free survival at 30 months and better continence and erectile-function outcomes. HIFI-2 adds post-radiation salvage evidence. Clinical data reduce, but do not eliminate, adoption risk.

Which competitors and substitutes pressure the business?

The June 2026 Investor Day presentation links installed-base growth to procedures. The moat remains conditional on utilization becoming recurring gross profit.

FocalTherics is not yet self-funding. FY2025 revenue was $70.5 million, up 1.6%, as HIFU growth offset much of the decline in ESWL and Distribution. Gross margin improved to 42.5%, but $54.7 million of operating expenses exceeded $30.0 million of gross profit, producing a $24.7 million operating loss and a $29.2 million net loss.

What does the annual financial profile reveal?

How much financing flexibility remains?

The company drew a €12 million EIB tranche in April 2026, extending liquidity while adding debt and warrant complexity. The FY2025 Form 10-K and Q1 filing indicate that more financing may be needed before profitability. Cash is being directed to commercialization, R&D, clinical studies, and liquidity rather than dividends or repurchases.

FOCL uses one-share-one-vote economics: each ADS represents one ordinary share. Ownership is nevertheless concentrated. The latest beneficial-ownership table used 37,751,519 shares outstanding as of February 27, 2026, with Soleus-related funds the largest disclosed holder and insiders collectively holding a substantial position.

Which holders have the greatest influence?

How is the board structured?

The FY2025 filing listed five directors. The chief executive and chair roles have been separated since May 2023: Ryan Rhodes leads the company and Lance Willsey chairs the board. The audit committee includes independent directors and a financial expert. French law reserves certain authority for the full board, and domestic-issuer status from January 1, 2026 raised U.S. compliance obligations.

Near-term growth still depends on prostate-cancer placements and utilization. Management is also developing Focal One for benign prostatic hyperplasia, or BPH, and deep infiltrating endometriosis. Both could expand the patient pool and utilization of a common platform, but each adds clinical, regulatory, and financing requirements before revenue is certain.

How large is the core HIFU growth opportunity?

Management’s June 2026 presentation showed HIFU revenue rising from $16 million in 2022 to $37 million in 2025 and used a $52 million midpoint for 2026 guidance. It also cited more than 300 U.S. hospitals in the pipeline. The commercial objective is to place systems, then increase procedures per system.

What could BPH and endometriosis add?

Platform reuse is the opportunity: one robot may eventually address several diseases. Each indication, however, needs evidence, regulatory work, training, reimbursement, and a launch. A research model should assign separate probabilities and timelines rather than treating pipeline programs as current revenue.

The opportunity is large relative to the company’s scale, making execution risk central. Filings emphasize financing, market acceptance, regulation, reimbursement, competition, suppliers, product liability, cybersecurity, foreign exchange, and medical-device demand. The most important risks connect directly to cash, utilization, and the legacy exit.

Which risks have the clearest financial impact?

Why is the legacy transition a special risk?

Exiting non-core businesses may improve revenue quality but can depress headline sales before HIFU replaces them. Distribution and ESWL were 47.0% of FY2025 revenue and 34.8% of Q1 2026 revenue. Historical consolidated growth is therefore a poor direct forecast. Working capital, customer obligations, service commitments, and restructuring costs also matter.

A model that extrapolates consolidated revenue would miss the transition. Forecast continuing HIFU operations from systems, utilization, recurring revenue, gross margin, and operating expenses; model the legacy exit separately; and include financing needs. Value depends on installed systems, procedures, commercial leverage, clinical spending, and the probability of new indications.

Which valuation drivers matter most?

For current market identity, the Nasdaq FOCL page confirms the trading symbol. The investor-day materials and future quarterly filings should be read together because management’s targets are forward-looking, while the financial statements show the actual pace of conversion.